| Name | Title | Contact Details |
|---|
More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn® Therapeutics ($FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control™ platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease. With Gene Traffic Control™ Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.
Our mission is simple. Deliver the most high-performance skincare and haircare solutions powered by the latest clinical advances to transform the look of your skin and hair. At the center of every formula is patented, proprietary NIA-114 technology that supercharges StriVectin`s clinically proven, award winning products.
Priority Pharmaceuticals is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
International Biometric Group is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
WellBe® is a digital health platform that provides voice-activated assistance with health questions, reminders, and entertainment using a smart speaker.